<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a retrospective analysis we assessed the data of 46 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), who had received more than 50 blood transfusions during the course of disease </plain></SENT>
<SENT sid="1" pm="."><plain>The number of units given ranged from 50 to 155 (mean 79) </plain></SENT>
<SENT sid="2" pm="."><plain>20 patients (RA n = 4, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> n = 12, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> n = 1, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/T n = 2, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> n = 1), followed up between 8 and 108 months (mean survival time 39.4 months), developed a secondary <z:mp ids='MP_0005638'>hemochromatosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>More than 40% of the patients showed signs of <z:hpo ids='HP_0001635'>heart failure</z:hpo>, in some cases accompanied by <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>11 patients also suffered from <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">hepatopathy</z:e> and 5 developed <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Secondary <z:mp ids='MP_0005638'>hemochromatosis</z:mp> was particularly common in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Refractory <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> secondary to <z:mp ids='MP_0005638'>hemochromatosis</z:mp> was the cause of <z:hpo ids='HP_0011420'>death</z:hpo> in 14 patients, whereas none died from hepatic insufficiency </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that the risk of secondary <z:mp ids='MP_0005638'>hemochromatosis</z:mp> should not be neglected in polytransfused patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In some cases, particularly those with favorable prognostic features of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, it may shorten life expectancy </plain></SENT>
<SENT sid="9" pm="."><plain>The availability of a new oral iron <z:chebi fb="0" ids="38161">chelator</z:chebi> (1,2-dimethyl-3-hydroxypyrid-4-one or L1) offers a promising and practicable approach to prevent this complication </plain></SENT>
</text></document>